Abstract
Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Current Respiratory Medicine Reviews
Title: Radiation Therapy in the Management of Lung Cancer
Volume: 7 Issue: 5
Author(s): Tarek Hijal, Jonathan Wan and Luis Souhami
Affiliation:
Keywords: Radiation therapy, non-small cell lung cancer, small-cell lung cancer, malignancy, radiosurgery, Inoperable Patients, Stereotactic Radiation Therapy, Chemoradiation, Palliative Radiotherapy, Thoracic Radiation Therapy
Abstract: Lung cancer is the most commonly diagnosed malignancy and the leading cause of cancer mortality worldwide. Radiation therapy (RT) plays an important role in the management of both small cell (SCLC) and non-small cell lung cancer (NSCLC), as 50 to 60% of patients diagnosed with lung cancer will require RT during the course of their disease. In NSCLC, in addition to the use of RT in advanced stage disease, inoperable patients with early-stage disease are now being treated with highly conformal hypofractionated RT as well as radiosurgery. In SCLC, the use of thoracic chemo-RT followed by prophylactic cranial irradiation (PCI) in limited-stage disease, and the use of PCI in extensive-stage disease have improved outcomes, and patient survival has steadily increased in the past decades. This article will review the role of RT in both SCLC and NSCLC, with emphasis at the most recent advances in the field as well as the topics of controversy.
Export Options
About this article
Cite this article as:
Hijal Tarek, Wan Jonathan and Souhami Luis, Radiation Therapy in the Management of Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189704
DOI https://dx.doi.org/10.2174/157339811797189704 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long Noncoding RNA C21orF96 Promotes the Migration, Invasion and Lymph Node Metastasis in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Formulations, Pharmacodynamic and Clinical Studies of Nanoparticles for Lung Cancer Therapy - An Overview
Current Drug Metabolism Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Connexin Genes as Promising Therapeutic Targets in Cancers
Current Pharmacogenomics Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Curcumin Targets in Inflammation and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Extracellular Matrix, Integrins, and Mesenchymal Cell Function in the Airways
Current Drug Targets The Role of Angiogenesis as a Prognostic Factor of Breast Cancer: Recent Review
Current Women`s Health Reviews Culture Supernatants from Lactobacillus plantarum Induce Necrosis on a Human Promyelocytic Leukemia Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Biomarkers for Risk Assessment of Particulate Matter Associated Lung Cancer
Current Drug Targets Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design Multi-Kinase Inhibitors
Current Medicinal Chemistry Topical Delivery of Antioxidants
Current Drug Delivery Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design